BIOMAT Database Logo BIOMAT Database Logo

Indinavir in cerebrospinal fluid of HIV-1-infected patients. 1997

L Ståhle, and C Martin, and J O Svensson, and A Sönnerborg

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D019469 Indinavir A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. Crixivan,Indinavir Sulfate,Indinavir, Sulfate (1:1),L-735 524,L-735,524,MK-639,L 735 524,L 735,524,L735 524,L735,524,MK 639,MK639,Sulfate, Indinavir

Related Publications

L Ståhle, and C Martin, and J O Svensson, and A Sönnerborg
Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1-infected patients.
March 1998, AIDS (London, England),
L Ståhle, and C Martin, and J O Svensson, and A Sönnerborg
Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.
November 2009, AIDS (London, England),
L Ståhle, and C Martin, and J O Svensson, and A Sönnerborg
Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients.
December 2000, AIDS (London, England),
L Ståhle, and C Martin, and J O Svensson, and A Sönnerborg
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy.
December 2000, Journal of acquired immune deficiency syndromes (1999),
L Ståhle, and C Martin, and J O Svensson, and A Sönnerborg
Macrophage-derived cytokines in the cerebrospinal fluid of HIV-1-infected patients.
February 1990, Acta neurologica,
L Ståhle, and C Martin, and J O Svensson, and A Sönnerborg
Cerebrospinal fluid catecholamine metabolites in HIV-infected patients.
March 1991, Journal of neuroscience research,
L Ståhle, and C Martin, and J O Svensson, and A Sönnerborg
Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
October 2007, European journal of clinical pharmacology,
L Ståhle, and C Martin, and J O Svensson, and A Sönnerborg
Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment.
November 2007, Journal of proteome research,
L Ståhle, and C Martin, and J O Svensson, and A Sönnerborg
Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients.
September 2003, Journal of clinical pharmacology,
L Ståhle, and C Martin, and J O Svensson, and A Sönnerborg
Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.
December 2010, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!